SCHEMBL901222

SCHEMBL901222

CC(C)(C)OC(=O)N1CC(N2CCN(c3ncccn3)C(=O)C2)C1

nearest known ligand 0.50

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 4/20 0.50
FAAH O00519 1/20 0.46
MGLL Q99685 1/20 0.46
MAPT P10636 1/20 0.43
POLB P06746 1/20 0.41
USP30 Q70CQ3 4/20 0.41
SCN9A Q15858 1/20 0.40
PIK3R1 P27986 1/20 0.39
PIK3CA P42336 1/20 0.39
DTYMK P23919 1/20 0.38
EGFR P00533 1/20 0.38
SRC P12931 1/20 0.38
ACHE P22303 1/20 0.37
MAPK1 P28482 1/20 0.37
NAMPT P43490 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL868914 0.84 GPR119 (0.54) GPR119MAPTPOLBUSP30DTYMK
SCHEMBL903464 0.83 GPR119 (0.52) GPR119USP30SCN9AMAPK1NAMPT
SCHEMBL2673770 0.80 USP2 (0.42) GPR119MAPTUSP30NAMPT
SCHEMBL900685 0.77 GPR119 (0.56) GPR119FAAHMGLLMAPTPOLB
SCHEMBL27090945 0.74 GPR119 (0.68) GPR119FAAHMGLL
SCHEMBL869784 0.72 MAPK1 (0.45) GPR119MAPTMAPK1NAMPT
SCHEMBL31343954 0.72 GPR119 (0.47) GPR119MGLLMAPTUSP30
SCHEMBL2896846 0.71 GPR119 (0.56) GPR119MAPTPOLBUSP30DTYMK
SCHEMBL3580204 0.71 GPR119 (0.67) GPR119FAAHMGLLMAPTPOLB
SCHEMBL1583147 0.71 GPR119 (0.58) GPR119MAPTPOLBUSP30DTYMK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8637498-B2 Oxopiperazine-azetidine amides and oxodiazepine-azetidine amides as monoacylglycerol lipase inhibitors JANSSEN PHARMACEUTICA, NV (BE) 2014-01-28 US disclosed
US-8637498-B2 Oxopiperazine-azetidine amides and oxodiazepine-azetidine amides as monoacylglycerol lipase inhibitors JANSSEN PHARMACEUTICA, NV (BE) 2014-01-28 US disclosed
EP-2621918-A1 OXOPIPERAZINE-AZETIDINE AMIDES AND OXODIAZEPINE-AZETIDINE AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS Janssen Pharmaceutica, N.V. (BE) 2013-08-07 EP disclosed
WO-2012044613-A1 OXOPIPERAZINE-AZETIDINE AMIDES AND OXODIAZEPINE-AZETIDINE AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2012-04-05 WO disclosed
WO-2012044613-A1 OXOPIPERAZINE-AZETIDINE AMIDES AND OXODIAZEPINE-AZETIDINE AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2012-04-05 WO disclosed
US-20120077797-A1 OXOPIPERAZINE-AZETIDINE AMIDES AND OXODIAZEPINE-AZETIDINE AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2012-03-29 US disclosed
US-20120077797-A1 OXOPIPERAZINE-AZETIDINE AMIDES AND OXODIAZEPINE-AZETIDINE AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2012-03-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120077797-A1 OXOPIPERAZINE-AZETIDINE AMIDES AND OXODIAZEPINE-AZETIDINE AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS LPL, PNLIP, LIPA GPR119 38/4885FAAH 46/4885MGLL 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.